Drug delivery strategies for poorly water-soluble drugs: The industrial perspective

Expert Opinion on Drug Delivery

Volumn 8, Issue 11, 2011, Pages 1481-1500

  Van Hoogevest, Peter ^a,b   Liu, Xiangli ^c   Fahr, Alfred ^c  

^a Phares AG   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Biorelevant solubilization; Drug delivery; Liposomes solubilization; Nano suspension; Poorly water soluble drug; Poorly water soluble drug dissolution; Solubilization

Indexed keywords

ALCOHOL; APREPITANT; ASCORBIC ACID PLUS VITAMIN B COMPLEX; BUSULFAN; CYCLODEXTRIN; CYCLOSPORIN A; FENOFIBRATE; FOSAPREPITANT; FUROSEMIDE; ITRACONAZOLE; LEUPRORELIN; LIPOSOME; LOPINAVIR PLUS RITONAVIR; MEGESTROL ACETATE; MITOMYCIN; PACLITAXEL; PHYTOMENADIONE; PROPYLENE GLYCOL; RAPAMYCIN; ROSUVASTATIN; TACROLIMUS; TECHNETIUM 99M; VORICONAZOLE;

DISPERSION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; LIPOPHILICITY; MICELLE; PHYSICAL CHEMISTRY; REVIEW; RISK BENEFIT ANALYSIS; STANDARD; SUSPENSION;

ANIMALS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; INTELLECTUAL PROPERTY; LIPOSOMES; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS; SALTS; SOLUBILITY; SUSPENSIONS;

EID: 80054794155     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.614228     Document Type: Review

References (123)

1. Fahr A, van Hoogevest P, May S, et al. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci 2005;26:251-65 (Pubitemid 41278632)
2. Commissioner of Food and Drugs. Nanotechnology Task Force Report, FDA Rockville MD 20857, 2007
3. Final Report from the EMEA/CHMPThink- Tank Group on Innovative Drug Development; 2007
4. Reflection Paper on Nanotechnology-based Medicinal Products for Human Use; 2006
5. Strickland CH. Nano-based drug and medical devices: FDA track record. Nanotechnol Law Bus 2007;4:179-88 (Pubitemid 47510236)
6. Guidance for Industry: Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. In: (CDER) USDoHaHSCfDEaR 2002
7. Draft Guidance on Doxorubicin HCl; 2010
8. Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv 2007;4:403-16 (Pubitemid 47249138)
9. Balbach S, Korn C. Pharmaceutical evaluation of early development candidates "the 100 mg-approach". Int J Pharm 2004;275:1-12 (Pubitemid 38481515)
10. Gopinathan S, Noraldeen A, Wilson AGE. Development and application of a high throughput screening for oral administration in drug discovery. Future Med Chem 2010;2:1392-8
11. Ahuja G, Pathak K. Porous carriers for controlled/modulated drug delivery. Indian J Pharm Sci 2009;71:599-607
12. Leigh S, Leigh MLS, Van Hoogevest P, et al. inventors; Phares Pharm Res NV assignee. Composition comprising low water soluble compounds within porous carriers. The Netherlands: 2004
13. Prendergast WF, Schafer HN. Nanocrystalline pharmaceutical patent litigation: the first case. Nanotechnol Law Bus 2008;5:157-61
14. Varma RK, Kaushal R, Junnarkar AY, et al. Polysorbate 80: a pharmacological study. Arzneimittelforschung 1985;35:804-8 (Pubitemid 15056752)
15. Masini E, Planchenault J, Pezziardi F, et al. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions 1985;16:470-7 (Pubitemid 16220968)
16. Bowers VD, Locker S, Ames S, et al. The hemodynamic effects of Cremophor-EL. Transplantation 1991;51:847-50
17. Eschalier A, Lavarenne J, Burtin C, et al. Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 1988;21:246-50
18. Eschalier A, Lavarenne J, Burtin C, et al. Acute hemodynamic effects of an antitumoral agent: elliptinium. Involvement of histamine release. Agents Actions 1986;17:441-8
19. Ennis M, Lorenz W, Gerland W. Modulation of histamine release from rat peritoneal mast cells by non-cytotoxic concentrations of the detergents Cremophor El (oxethylated castor oil) and Triton X100. A possible explanation for unexpected adverse drug reactions? Agents Actions 1986;18:235-8 (Pubitemid 16113264)
20. Ennis M, Lorenz W, Kapp B, et al. Comparison of the histamine-releasing activity of cremophor E1 and some of its derivatives in two experimental models: the in vivo anaesthetized dog and in vitro rat peritoneal mast cells. Agents Actions 1985;16:265-8 (Pubitemid 15116711)
21. Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977;7:63-7 (Pubitemid 8070781)
22. Lorenz W, Schmal A, Schult H, et al. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in cremophor El and development of a compound with reduced toxicity. Agents Actions 1982;12:64-80 (Pubitemid 12076385)
23. Thaysen G. Applications of Solutol HS 15 In: ExAct B; 1999. p. 7
24. Teelmann K, Schlappi B, Schupbach M, et al. Preclinical safety evaluation of intravenously administered mixed micelles. Arzneimittelforschung 1984;34:1517-23 (Pubitemid 15203496)
25. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201-30 (Pubitemid 38221966)
26. Fahr A, van Hoogevest P, Kuntsche J, et al. Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery? J Liposome Res 2006;16:281-301 (Pubitemid 44359001)
27. Dai WG, Pollock-Dove C, Dong LC, et al. Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation. Adv Drug Deliv Rev 2008;60:657-72
28. Dai WG, Dong LC, Li S, et al. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material. Int J Pharm 2007;336:1-11 (Pubitemid 46551550)
29. Mansky P, Dai WG, Li S, et al. Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing. J Pharm Sci 2007;96:1548-63 (Pubitemid 46953770)
30. Lee YC, Zocharski PD, Samas B. An intravenous formulation decision tree for discovery compound formulation development. Int J Pharm 2003;253:111-19 (Pubitemid 36197836)
31. Neervannan S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug MetabToxicol 2006;2:715-31 (Pubitemid 46118317)
32. Li P, Zhao L. Developing early formulations: practice and perspective. Int J Pharm 2007;341:1-19 (Pubitemid 47088122)
33. Van Hoogevest P, Rogue V, Brumec M, et al. Instant solubilization of poorly water-soluble drugs by in-situ loading of aqueous phospholipid dispersions suitable for parenteral administration. PDA J Pharm Sci Technol 2006;60:366-77
34. Van Hoogevest P, Liu X, Fahr A, et al. Role of phospholipids in the oral and parenteral delivery of poorly water soluble drugs. J Drug Deliv Sci Technol 2011;21:5-16
35. Shah T, Patel D, Hirani J, et al. Nanosuspensions as a drug delivery system: a comprehensive review. Drug Delivery Technol 2007;7:42-53
36. Niwa T, Miura S, Danjo K. Universal wet-milling technique to prepare oral nanosuspensions focused on discovery and pre-clinical animal studies. Development of particle design method. Int J Pharm 2011;405:218-27
37. Bittner B, Mountfield RJ. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Devel 2002;5:59-71 (Pubitemid 34453243)
38. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20
39. Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci 2010;99:4940-54
40. Dressman J, Butler J, Hempenstall J, et al. The BCS: where do we go from here ? Pharm Technol 2001;25:68-76
41. Corrigan OI. The biopharmaceutics drug classification and drugs administered in extended release (ER) formulations. Adv Exp Med Biol 1997;423:111-28 (Pubitemid 27347196)
42. Dressman JB, Amidon GL, Reppas C, et al. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998;15:11-22 (Pubitemid 28080861)
43. Nicolaides E, Galia E, Efthymiopoulos C, et al. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res 1999;16:1876-82 (Pubitemid 30040705)
44. Lobenberg R, Kramer J, Shah VP, et al. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res 2000;17:439-44 (Pubitemid 30395299)
45. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000;11(Suppl 2):S73-80
46. Kloefer B, Van Hoogevest P, Moloney R, et al. Study of a standardized taurocholate-lecithin powder for preparing the biorelevant media FeSSIF and FaSSIF dissolution technologies. Dissol Technol 2010;17:6-13
47. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev 2011;63:427-40
48. Juenemann D, Jantratid E, Wagner C, et al. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Eur J Pharm Biopharm 2011;77:257-64
49. Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 1995;125:309-13
50. Shono Y, Jantratid E, Kesisoglou F, et al. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm 2010;76:95-104
51. Grunkemeyer JL, Mirejovsky D, Lenaz L, et al. Significant improvement of oral bioavailability of a poorly soluble compound. AAPS; Nashville, TN, USA: 2005
52. Guzman HR, Tawa M, Zhang Z, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 2007;96:2686-702 (Pubitemid 47597818)
53. Hecq J, Deleers M, Fanara D, et al. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb- 35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm 2006;64:360-8 (Pubitemid 44585201)
54. Tong WT. Salt screening and selection: new challenges and considerations in the modern pharmaceutical research and development paradigm In: Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter WR. editors. Developing Oral Dosage Forms: pharmaceutical theory and practice. Academic Press; Burlington, London, San Diego, New York; 2009. p. 75-85
55. Kojima T, Tsutsumi S, Yamamoto K, et al. High-throughput cocrystal slurry screening by use of in situ Raman microscopy and multi-well plate. Int J Pharm 2010;399:52-9
56. Zimmerman J. inventor, Ciba-Geigy AG, assignee. Pyrimidin derivatives and process for their preparation. 1993
57. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4
58. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 2004;44:158-62 (Pubitemid 38114314)
59. Emend Injection Drug Description. Available from: http://www.rxlist.com/ emend-injection-drug.htm
60. Webb MS, Rebstein P, Lamson W, et al. Liposomal drug delivery: recent patents and emerging opportunities. Recent Patents Drug Deliv Formulation 2007;I:185-94
61. Bhavna, Ali M, Baboota S, Ali J. Patents on nanoparticulate drug delivery -a review. Recent Patents Drug Deliv Formulation 2008;2:83-9 (Pubitemid 351546437)
62. Fu Q, Sun J, Zhang W, et al. Nanoparticle Albumin-Bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Patents Anticancer Drug Discov 2009;4:262-72
63. Liversidge GG, Cundy KC, Bishop JF, et al. inventors; Sterling Drug, Inc., assignee. Surface modified drug nanoparticles. US 5,145,684: 1992
64. Czekai DA, Seaman LP. inventors; Eastman Kodak, assignee. Continuous method of grinding pharmaceutical substances. US 5,718,388: 1998
65. Juhnke M, Berghausen J, Timpe C. Accelerated formulation development for nanomilled active pharmaceutical ingredients using a screening approach chemical engineering & technology. Chem Eng Technol 2010;33:1412-18
66. Lakshmi P, Kumar GH. Nano-suspension technology: a review. Int J Pharm Pharm 2010;2:35-40
67. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007;59:645-66 (Pubitemid 47299263)
68. Cydex Pharmaceuticals, Inc.: Marketed products. Available from: http://cydexpharma.com/approvedproducts.html
69. Muller BW, Brauns U. inventors; Janssen Pharmaceutica N.V., assignee. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation. US 6,407,079: 2002
70. Stella V, Rajewski R. inventors; University of Kansas assignee. Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof. US 5134127: 1992
71. Pipkin JD, Mosher GL, Hecker DB. inventors; CyDex Pharmaceuticals, Inc., assignee. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof. US 7629331: 2009
72. Antle V. inventor, CyDex Pharmaceuticals, Inc., assignee. Sulfoalkyl ether cyclodextrin compositions. US 7,635,773: 2009
73. Leigh S, Leigh MLS, Van Hoogevest P. inventors; Phares Pharmaceutical Research N.V., assignee. Crystal forms of astaxanthin. US 7,563,935: 2009
74. Gellie B. Intellectual properties and crystalline forms: how to get an European Patent on crystalline forms? 5th Bologna convention on crystal form Bologna; 2010
75. Fricker G, Kromp T, Wendel A, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res 2010;27:1469-86
76. Mullertz A, Ogbonna A, Ren S, et al. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 2010; In press
77. Kuentz M. Oral self-emulsifyng drug delivery sytems, from biopharmaceutical to technical formulation aspects. J Drug Deliv Sci Technol 2011;21:17-20
78. Mistry RB, Sheth NS. A review : self emulsifying drug delivery system. Int J Pharm Pharm Sci 2011;3:23-8
79. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004;3:1023-35 (Pubitemid 39642365)
80. Gould S, Scott RC. 2-Hydroxypropylbeta- cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 2005;43:1451-9 (Pubitemid 40961909)
81. Breitenbach J, Magerlein M. Melt-Extruded Molecular Dispersions. In: Ghebre Sellassie I, Martin C. editors. Pharmaceutical extrusion technology. Marcel Dekker; New York, 2003. p. 245-60
82. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281-302
83. Prodduturi S, Urman KL, Otaigbe JU, et al. Stabilization of hot-melt extrusion formulations containing solid solutions using polymer blends. AAPS PharmSciTech 2007;8:E1-10 (Pubitemid 47053749)
84. Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol 2009;61:1571-86
85. Sporanox product. Available from: http://www.rxlist.com/sporanox-drug.htm
86. Intelence product. Available from: http://www.rxlist.com/intelence-drug. htm
87. Prograf product. Available from: http://www.rxlist.com/prograf-drug.htm
88. Crestor product. Available from: http://www.rxlist.com/crestor-drug.htm
89. Gris-PEG product. Available from: http://www.rxlist.com/gris-peg-drug.htm
90. Aoyagi N, Ogata H, Kaniwa N, et al. Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets. J Pharmacobiodyn 1982;5:120-4 (Pubitemid 12121224)
91. Kaletra product. Available from: http://www.rxlist.com/kaletra-tablets- drug.htm
92. Rapamune product. Available from: http://www.rxlist.com/rapamune-drug.htm
93. Emend oral product. Available from: http://www.rxlist.com/emend-drug.htm
94. Wu Y, Loper A, Landis E, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 2004;285:135-46 (Pubitemid 39361543)
95. Megace ES product. Available from: http://www.rxlist.com/megace-es-drug. htm
96. Megace ES product UK. Available from: http://www.medicines.org.uk/EMC/ medicine/346/SPC/Megace+160+mg +Tablets/
97. Deschamps B, Musaji N, Gillespie JA. Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. Int J Nanomedicine 2009;4:185-92
98. Miele E, Spinelli GP, Tomao F, et al. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009;4:99-105
99. Micha JP, Goldstein BH, Birk CL, et al. Case report: Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol 2006;100:437-43
100. Abraxane product. Available from: http://www.rxlist.com/abraxane-drug.htm
101. Albumin product. Available from: http://www.orgyn.com/resources/genrx/ D000114.asp
102. Invega sustenna product. Available from: http://www.rxlist.com/invega- sustennadrug.htm
103. Ambisome product. Available from: www.ambisome.com
104. Veerareddy PR, Vobalaboina V. Lipid-based formulations of amphotericin B. Drugs Today (Barc) 2004;40:133-45 (Pubitemid 38387618)
105. EMA 2008
106. Van Hoogevest P, Fankhauser P. An industrial liposomal dosage form for muramyl-tripeptide-phosphatidyl ethanolamine (MTP-PE). In: Fidler IJ, Lopez-Berestein G. editors. Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, Inc; New York 1989. p. 453
107. Schwartz RS, Tanaka Y, Fidler IJ, et al. Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes. J Clin Invest 1985;75:1965-72 (Pubitemid 15233585)
108. Schumann G, van Hoogevest P, Fankhauser P, et al.Comparison of free and liposomal MTP-PE. Pharmacological and toxicological aspects. In: Fidler IJ, Lopez-Berestein G. editors. Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, Inc; New York; 1989. p. 191
109. Braun DG, van Hoogevest P, Schumann G. Adjuvants: theory and practical applications: muramyltripeptidephosphatidylethanolamine MTP-PE-A Muramyldipeptide derivative with lipophilic properties. Oxford Butterworth-Heinemann; 1994
110. Visudyne product. Available from: www. visudyne.com
111. Desai NR, Agha BJ, Kale KM. inventors; QLT Phototherapeutics, Inc., assignee. Liposome compositions of porphyrin photosensitizers. Canada: 2000
112. Chowdhary RK, Shariff I, Dolphin D. Drug release characteristics of lipid based benzoporphyrin derivative. J Pharm Pharm Sci 2003;6:13-19 (Pubitemid 37207238)
113. Richter AM, Cerruti-Sola S, Sternberg ED, et al. Biodistribution of tritiated benzoporphyrin derivative (3HBPD- MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B 1990;5:231-44
114. Visudyne European Public Assessment Report EMA; 2006
115. Definity product. Available from: http://www.rxlist.com/definity-drug.htm
116. Luigetti R. Reflection paper on the pharmaceutical development of intravenous medicinal products containing active substances solubilised in micellar systems (non-polymeric surfactants) DRAFT. 2010
117. Reflection paper on nanotechnology-based medicinal products for human use In: (CHMP) CFMPFHU; 2006
118. Pena C. A FDA perspective on nanomedicine: current initiatives in the US. In: Commisioner Oot; 2010
119. Manual of policies and procedures MAPP5015.9. Reporting format in nanotechnology information in CMC review 6/3/2010. In: Science CodearOop; 2010
120. Messner M, Kurkov SV, Flavia-Piera R, et al. Self-assembly of cyclodextrins: the effect of the guest molecule. Int J Pharm 2011;408:235-47
121. Messner M, Kurkov SV, Brewster ME, et al. Self-assembly of cyclodextrin complexes: aggregation of hydrocortisone/cyclodextrin complexes. Int J Pharm 2011;407:174-83
122. Van't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010 54: 2042-50
123. Teagarden DL, Baker DS. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur J Pharm Sci 2002;15:115-33 (Pubitemid 34155373)